ATE364617T1 - Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon - Google Patents

Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon

Info

Publication number
ATE364617T1
ATE364617T1 AT99965256T AT99965256T ATE364617T1 AT E364617 T1 ATE364617 T1 AT E364617T1 AT 99965256 T AT99965256 T AT 99965256T AT 99965256 T AT99965256 T AT 99965256T AT E364617 T1 ATE364617 T1 AT E364617T1
Authority
AT
Austria
Prior art keywords
ctgf
fragments
methods
applications
growth factor
Prior art date
Application number
AT99965256T
Other languages
English (en)
Inventor
Gary Grotendorst
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of ATE364617T1 publication Critical patent/ATE364617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT99965256T 1998-12-14 1999-12-14 Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon ATE364617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11224098P 1998-12-14 1998-12-14
US11224198P 1998-12-14 1998-12-14

Publications (1)

Publication Number Publication Date
ATE364617T1 true ATE364617T1 (de) 2007-07-15

Family

ID=26809725

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99966224T ATE391724T1 (de) 1998-12-14 1999-12-14 FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)
AT99965256T ATE364617T1 (de) 1998-12-14 1999-12-14 Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99966224T ATE391724T1 (de) 1998-12-14 1999-12-14 FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)

Country Status (16)

Country Link
US (3) US6492129B1 (de)
EP (2) EP1140969B1 (de)
JP (2) JP4634614B2 (de)
KR (2) KR100664626B1 (de)
CN (3) CN1170849C (de)
AT (2) ATE391724T1 (de)
AU (3) AU773278B2 (de)
CA (2) CA2354456A1 (de)
CY (1) CY1108860T1 (de)
DE (2) DE69938507T2 (de)
DK (1) DK1140969T3 (de)
ES (2) ES2304811T3 (de)
HK (2) HK1041268B (de)
MX (1) MXPA01005949A (de)
PT (1) PT1140969E (de)
WO (2) WO2000035939A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
NZ271488A (en) 1994-07-12 1998-01-26 Human Genome Sciences Inc Connective tissue growth factor-2 (ctgf-2)
CA2354456A1 (en) * 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU2001276868A1 (en) * 2000-07-11 2002-01-21 Human Genome Sciences, Inc. Connective tissue growth factor-2
EP1434993B1 (de) * 2001-09-18 2013-04-24 Fibrogen, Inc. Verfahren zum testen des bindegewebe-wachstumsfaktors
WO2003035868A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
CN1602207A (zh) * 2001-12-11 2005-03-30 法布罗根股份有限公司 抑制眼病理过程的方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
DE602005008013D1 (de) * 2004-02-11 2008-08-21 Fibrogen Inc Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
ZA200607588B (en) * 2004-02-11 2008-05-28 Fibrogen Inc CTGF as target for the therapy of diabetic nephropathy
MXPA06012576A (es) 2004-04-28 2007-01-31 Fibrogen Inc Tratamientos para cancer pancreatico.
JPWO2005116194A1 (ja) * 2004-05-25 2008-04-03 独立行政法人理化学研究所 試験管内筋繊維形成のための筋芽細胞又は筋芽細胞様細胞培養法
EP1692935A1 (de) * 2005-02-22 2006-08-23 Boehringer Ingelheim International GmbH Transgenes Tier als Modell für Lungenkrankheiten des Menschen
US8088381B2 (en) 2005-05-05 2012-01-03 Fibrogen, Inc. Methods of treatment of cardiovascular disease using anti-CTGF agents
EP1976877B2 (de) 2005-11-30 2016-10-05 AbbVie Inc. Monoklonale antikörper gegen das amyloid-beta-protein und anwendungen davon
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
US20100034892A1 (en) * 2006-08-30 2010-02-11 The Trustees Of Columbia University In The City Of New York Treatment for bone formation disorders by growth factor delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
US8617877B2 (en) * 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
JP5420668B2 (ja) 2008-08-25 2014-02-19 エクスカリアード・ファーマシューティカルズ，インコーポレイテッド 結合組織成長因子を対象とするアンチセンスオリゴヌクレオチドおよびその使用
WO2010027830A2 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
US8771692B2 (en) 2009-07-02 2014-07-08 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
EP2550001B1 (de) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna-interferenz bei augenerkrankungen
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
CN103635197A (zh) 2011-02-02 2014-03-12 埃克斯利尔德生物制药公司 使用靶向结缔组织生长因子(ctgf)的反义化合物治疗疤痕疙瘩或肥大性疤痕的方法
EA029290B1 (ru) * 2011-12-22 2018-03-30 Астеллас Фарма Инк. Новое антитело против ctgf человека
EP2844291B1 (de) 2012-05-03 2019-02-13 Fibrogen, Inc. Verfahren zur behandlung von idiopathischer lungenfibrose
US9132171B2 (en) 2012-05-23 2015-09-15 Wisconsin Alumni Research Foundation Test of insulin as a drug to reduce restenosis of vessels
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
AU2016279897A1 (en) * 2015-06-15 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN111424035A (zh) * 2020-04-13 2020-07-17 西南大学 基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US392024A (en) * 1888-10-30 Jjett
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
NZ271488A (en) 1994-07-12 1998-01-26 Human Genome Sciences Inc Connective tissue growth factor-2 (ctgf-2)
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5688915A (en) 1995-06-01 1997-11-18 The University Of Medicine And Dentistry Of New Jersey Long term maintenance of lymphocytes in vitro
EP0871705A4 (de) * 1995-06-05 2000-01-26 Human Genome Sciences Inc Menschlicher ccn-ähnlicher wachstumsfaktor
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
WO1999033878A1 (fr) 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
WO1999042583A1 (en) 1998-02-20 1999-08-26 Zymogenetics, Inc. Connective tissue growth factor homologs
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
CA2354456A1 (en) * 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies

Also Published As

Publication number Publication date
CA2354422A1 (en) 2000-06-22
KR100664625B1 (ko) 2007-01-04
ES2288321T3 (es) 2008-01-01
AU2181900A (en) 2000-07-03
WO2000035936A1 (en) 2000-06-22
HK1041005B (zh) 2007-11-09
JP4722290B2 (ja) 2011-07-13
AU773278B2 (en) 2004-05-20
EP1140964A2 (de) 2001-10-10
AU775391B2 (en) 2004-07-29
CA2354456A1 (en) 2000-06-22
DE69938507D1 (en) 2008-05-21
HK1041268B (zh) 2009-02-27
DE69936315D1 (de) 2007-07-26
CN1187370C (zh) 2005-02-02
DK1140969T3 (da) 2007-09-17
CN1660911A (zh) 2005-08-31
EP1140969A4 (de) 2003-07-23
EP1140969B1 (de) 2007-06-13
PT1140969E (pt) 2007-08-30
US20100190838A1 (en) 2010-07-29
HK1041268A1 (en) 2002-07-05
KR20010101194A (ko) 2001-11-14
US7718177B2 (en) 2010-05-18
EP1140964B1 (de) 2008-04-09
AU2004205171A1 (en) 2004-09-16
HK1041005A1 (en) 2002-06-28
WO2000035939A2 (en) 2000-06-22
ATE391724T1 (de) 2008-04-15
WO2000035939A3 (en) 2000-10-12
KR100664626B1 (ko) 2007-01-04
DE69936315T2 (de) 2008-02-14
JP2002532082A (ja) 2002-10-02
CY1108860T1 (el) 2014-07-02
CN1170849C (zh) 2004-10-13
ES2304811T3 (es) 2008-10-16
CN1334820A (zh) 2002-02-06
EP1140964A4 (de) 2003-06-18
KR20010101207A (ko) 2001-11-14
EP1140969A1 (de) 2001-10-10
AU2004205171B2 (en) 2007-08-09
AU3121100A (en) 2000-07-03
US6492129B1 (en) 2002-12-10
CN1334819A (zh) 2002-02-06
JP4634614B2 (ja) 2011-02-16
JP2002532084A (ja) 2002-10-02
DE69938507T2 (de) 2009-06-10
MXPA01005949A (es) 2002-09-18
US20030180300A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
ATE364617T1 (de) Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
BR0011251A (pt) Composições de a-beta peptìdeo e processos para a produção das mesmas
DE69632313D1 (de) Desorbierbare extrazelluläre matrix für rekonstruktion eines knorpelgewebes
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
DK0592562T3 (da) BMP-9-præparater
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
EP0832100A4 (de) Neuartige metalloprotease-inhibitoren, diese enthaltende pharmazeutische zusammensetzungen und anwendungsverfahren
ATE199639T1 (de) Mittel zur behandlung von keratinmaterial, das mindestens ein silikongepfropftes polymer mit einem mit nicht-silikon organischen monomeren gepfropften polysiloxangerüst und mindestens einen flüssigen c11-26 kohlenwasserstoff enthält
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60108094D1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
RU95105983A (ru) Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе
ATE222901T1 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
ATE425247T1 (de) Synthetische peptide und ihre vorbeugende oder therapeutische anwendung für krebsinvasion und metastasen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140969

Country of ref document: EP